Syndax Pharmaceuticals, Inc. (SNDX)

NASDAQ: SNDX · IEX Real-Time Price · USD
16.32
1.14 (7.51%)
May 27, 2022 4:00 PM EDT - Market closed
Market Cap917.71M
Revenue (ttm)139.33M
Net Income (ttm)15.48M
Shares Out56.23M
EPS (ttm)0.27
PE Ratio59.56
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume483,163
Open15.27
Previous Close15.18
Day's Range14.70 - 16.35
52-Week Range13.27 - 22.71
Beta1.53
AnalystsBuy
Price Target33.51 (+105.3%)
Earnings DateMay 9, 2022

About SNDX

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic ...

IndustryBiotechnology
IPO DateMar 3, 2016
CEOArlene Morris
Employees59
Stock ExchangeNASDAQ
Ticker SymbolSNDX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for SNDX stock is "Buy." The 12-month stock price forecast is 33.51, which is an increase of 105.33% from the latest price.

Price Target
$33.51
(105.33% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Syndax Announces Participation at Two Upcoming Investor Conferences

WALTHAM, Mass. , May 26, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...

1 day ago - PRNewsWire

Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day

WALTHAM, Mass. , May 11, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...

2 weeks ago - PRNewsWire

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update

– Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA filings in 2023 – – BEAT-AML and AUGMENT-102 trials assessing re...

2 weeks ago - PRNewsWire

Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022

WALTHAM, Mass. , May 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline o...

3 weeks ago - PRNewsWire

Do Penny Stocks Ever Make Money? Here Are 7 Success Stories

Penny stocks can make money. Success stories include Advanced Micro Devices, a former penny stock that earned a $3.2 billion net income in 2021.

Other symbols:AMDAPPSBBQEGYEXPIJYNT
1 month ago - InvestorPlace

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WALTHAM, Mass., March 4, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...

2 months ago - PRNewsWire

Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update

WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...

2 months ago - PRNewsWire

Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer

WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...

2 months ago - PRNewsWire

Syndax Announces Participation at Two Upcoming Investor Conferences

WALTHAM, Mass., Feb. 28, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...

2 months ago - PRNewsWire

Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W.

WALTHAM, Mass., Feb. 3, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline o...

3 months ago - PRNewsWire

Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference

WALTHAM, Mass., Jan. 20, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...

4 months ago - PRNewsWire

Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline o...

4 months ago - PRNewsWire

Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myelo...

WALTHAM, Mass., Dec. 22, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...

5 months ago - PRNewsWire

Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional S...

WALTHAM, Mass., Dec. 20, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...

5 months ago - PRNewsWire

Syndax Announces Pricing of $75.3 Million Public Offering

WALTHAM, Mass., Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...

5 months ago - PRNewsWire

Syndax Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...

5 months ago - PRNewsWire

Syndax Pharma Posts Additional Data On Clinical Activity, Responses From Early-Stage Leukemia Trial

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) revealed updated data from the Phase 1 dose-escalation portion of the AUGMENT-101 trial of SNDX-5613 in patients with mutant nucleophosmin (mNPM1) or mixed-line...

5 months ago - Benzinga

Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durab...

WALTHAM, Mass., Dec. 13, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...

5 months ago - PRNewsWire

Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in...

WALTHAM, Mass., Dec. 11, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline ...

5 months ago - PRNewsWire

Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab

WALTHAM, Mass., Dec. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed...

5 months ago - PRNewsWire

Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update

WALTHAM, Mass., Nov. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline ...

6 months ago - PRNewsWire

Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021

WALTHAM, Mass., Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline o...

6 months ago - PRNewsWire

Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions a...

WALTHAM, Mass., Nov. 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announce...

6 months ago - PRNewsWire

Can Syndax (SNDX) Climb 48% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 47.7% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate rev...

7 months ago - Zacks Investment Research